Optiver Holding
MGX icon

Optiver Holding’s Metagenomi Therapeutics MGX Stock Holding History

Optiver Holding’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Sell
2
-16
-89% -$21 ﹤0.01% 2745
2026
Q1 		$24 Hold
18
– – ﹤0.01% 2266
2025
Q4 		$29 Hold
18
– – ﹤0.01% 2408
2025
Q3 		$43 Buy
+18
New +$37 ﹤0.01% 2626

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Optiver Holding's MGX Position: Q2 2026 in Review

Optiver Holding reduced its Metagenomi Therapeutics (MGX) stake by 89% in Q2 2026, selling an estimated $21 and leaving 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

Optiver Holding first reported a position in MGX in Q3 2025 and has held it in 4 quarters since. The position peaked at $43 in Q3 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Optiver Holding held 2 shares of Metagenomi Therapeutics worth $2 as of Q2 2026.
  • Optiver Holding sold 16 Metagenomi Therapeutics shares in Q2 2026, an estimated $21.
  • Metagenomi Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2745 holding.
  • Optiver Holding first reported a position in Metagenomi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Metagenomi Therapeutics position peaked at $43 in Q3 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.